RECURSION PHARMACEUTICALS, INC. Increase (Decrease) in Contract with Customer, Liability
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Increase (Decrease) in Contract with Customer, Liability of -$9.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$7.30M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$2.25M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$6.76M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$6.63M, a 269.29% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$36.77M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$28.04M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$41.08M, a 137.23% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $110.32M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$9.55M 10-Q · filed 2026-08-05 | -$16.31M derived: sum of 3 quarters · filed 2026-08-05 | -$22.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$2.25M 10-Q · filed 2026-05-06 | -$9.01M derived: sum of 2 quarters · filed 2026-05-06 | -$15.64M derived: sum of 3 quarters · filed 2026-05-06 | -$29.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$6.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$13.39M derived: sum of 2 quarters · filed 2026-02-25 | -$27.01M derived: sum of 3 quarters · filed 2026-08-05 | -$36.77M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$6.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$20.25M derived: sum of 2 quarters · filed 2026-08-05 | -$30.01M 10-Q · filed 2025-11-05 | -$35.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$13.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$23.38M 10-Q · filed 2026-08-05 | -$29.05M derived: sum of 3 quarters · filed 2026-08-05 | -$25.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$9.76M 10-Q · filed 2026-05-06 | -$15.43M derived: sum of 2 quarters · filed 2026-05-06 | -$11.51M derived: sum of 3 quarters · filed 2026-05-06 | -$24.14M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.75M derived: sum of 2 quarters · filed 2026-02-25 | -$14.38M derived: sum of 3 quarters · filed 2026-02-25 | -$28.04M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$8.72M derived: sum of 2 quarters · filed 2025-11-05 | -$22.37M 10-Q · filed 2025-11-05 | -$30.09M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$12.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$26.29M 10-Q · filed 2025-08-05 | -$34.01M derived: sum of 3 quarters · filed 2026-02-25 | -$44.17M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$13.65M 10-Q · filed 2025-05-05 | -$21.37M derived: sum of 2 quarters · filed 2026-02-25 | -$31.53M derived: sum of 3 quarters · filed 2026-02-25 | -$42.60M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$7.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$17.88M derived: sum of 2 quarters · filed 2026-02-25 | -$28.94M derived: sum of 3 quarters · filed 2026-02-25 | -$41.08M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$10.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$21.23M derived: sum of 2 quarters · filed 2024-11-06 | -$33.36M 10-Q · filed 2024-11-06 | -$47.03M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$11.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$23.20M 10-Q · filed 2024-08-08 | -$36.88M derived: sum of 3 quarters · filed 2025-02-28 | -$49.93M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$12.13M 10-Q · filed 2024-05-09 | -$25.81M derived: sum of 2 quarters · filed 2025-02-28 | -$38.86M derived: sum of 3 quarters · filed 2025-02-28 | -$46.52M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$13.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$26.73M derived: sum of 2 quarters · filed 2025-02-28 | -$34.38M derived: sum of 3 quarters · filed 2025-02-28 | $110.32M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$13.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$20.71M derived: sum of 2 quarters · filed 2023-11-09 | $124.00M 10-Q · filed 2023-11-09 | $121.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$7.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $137.05M 10-Q · filed 2023-08-08 | $134.55M derived: sum of 3 quarters · filed 2024-02-29 | $132.05M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $144.70M 10-Q · filed 2023-05-08 | $142.20M derived: sum of 2 quarters · filed 2024-02-29 | $139.70M derived: sum of 3 quarters · filed 2024-02-29 | $137.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$5.00M derived: sum of 2 quarters · filed 2024-02-29 | -$7.50M derived: sum of 3 quarters · filed 2024-02-29 | -$10.00M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$5.00M derived: sum of 2 quarters · filed 2022-11-08 | -$7.50M 10-Q · filed 2022-11-08 | -$10.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$5.00M 10-Q · filed 2022-08-09 | -$7.50M derived: sum of 3 quarters · filed 2023-02-27 | $21.67M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$2.50M 10-Q · filed 2022-05-10 | -$5.00M derived: sum of 2 quarters · filed 2023-02-27 | $24.17M derived: sum of 3 quarters · filed 2023-02-27 | $24.17M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $26.67M derived: sum of 2 quarters · filed 2023-02-27 | $26.67M derived: sum of 3 quarters · filed 2023-02-27 | $26.67M 10-K · filed 2023-02-27 |
| 2020-09-30 | $29.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $29.17M derived: sum of 2 quarters · filed 2021-11-10 | $29.17M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |